Review



cwith primary antibodies  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Proteintech cwith primary antibodies
    Cwith Primary Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith primary antibodies/product/Proteintech
    Average 94 stars, based on 55 article reviews
    cwith primary antibodies - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    cwith primary antibody  (EpiCypher)
    96
    EpiCypher cwith primary antibody
    Cwith Primary Antibody, supplied by EpiCypher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith primary antibody/product/EpiCypher
    Average 96 stars, based on 1 article reviews
    cwith primary antibody - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    cwith primary antibodies against titin  (Developmental Studies Hybridoma Bank)
    95
    Developmental Studies Hybridoma Bank cwith primary antibodies against titin
    Cwith Primary Antibodies Against Titin, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith primary antibodies against titin/product/Developmental Studies Hybridoma Bank
    Average 95 stars, based on 1 article reviews
    cwith primary antibodies against titin - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    4◦cwith primary antibodies against cd31  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc 4◦cwith primary antibodies against cd31
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    4◦Cwith Primary Antibodies Against Cd31, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/4◦cwith primary antibodies against cd31/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    4◦cwith primary antibodies against cd31 - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    cwith primary antibodies  (Proteintech)
    94
    Proteintech cwith primary antibodies
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    Cwith Primary Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith primary antibodies/product/Proteintech
    Average 94 stars, based on 1 article reviews
    cwith primary antibodies - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    4◦cwith primary anti zo-1  (Proteintech)
    97
    Proteintech 4◦cwith primary anti zo-1
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    4◦Cwith Primary Anti Zo 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/4◦cwith primary anti zo-1/product/Proteintech
    Average 97 stars, based on 1 article reviews
    4◦cwith primary anti zo-1 - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    ◦cwith primary antibodies targeting β actin  (Proteintech)
    96
    Proteintech ◦cwith primary antibodies targeting β actin
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    ◦Cwith Primary Antibodies Targeting β Actin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/◦cwith primary antibodies targeting β actin/product/Proteintech
    Average 96 stars, based on 1 article reviews
    ◦cwith primary antibodies targeting β actin - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    cwith primary antibodies against th  (Novus Biologicals)
    97
    Novus Biologicals cwith primary antibodies against th
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    Cwith Primary Antibodies Against Th, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith primary antibodies against th/product/Novus Biologicals
    Average 97 stars, based on 1 article reviews
    cwith primary antibodies against th - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    cwith primary antibody against plxnb3  (Danaher Inc)
    86
    Danaher Inc cwith primary antibody against plxnb3
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    Cwith Primary Antibody Against Plxnb3, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith primary antibody against plxnb3/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    cwith primary antibody against plxnb3 - by Bioz Stars, 2026-03
    86/100 stars
    		  Buy from Supplier
    ◦ cwith primary antibodies  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology ◦ cwith primary antibodies
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    ◦ Cwith Primary Antibodies, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/◦ cwith primary antibodies/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    ◦ cwith primary antibodies - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    cwith appropriate primary trail antibody  (Cell Signaling Technology Inc)
    99
    Cell Signaling Technology Inc cwith appropriate primary trail antibody
    FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
    Cwith Appropriate Primary Trail Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cwith appropriate primary trail antibody/product/Cell Signaling Technology Inc
    Average 99 stars, based on 1 article reviews
    cwith appropriate primary trail antibody - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 1 Cerebral vessels lesion and elevated CD31 levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.

    Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

    Article Title: Pathological angiogenesis was associated with cerebrovascular lesion and neurodegeneration in Alzheimer's disease.

    doi: 10.1002/alz.14521

    Figure Lengend Snippet: FIGURE 1 Cerebral vessels lesion and elevated CD31 levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.

    Article Snippet: The sections were then blocked with blocking buffer (5% normal goat serum, 0.3% Triton ×-100 in phosphate buffered saline [PBS]) for 1 h at room temperature and incubated overnight at 4◦Cwith primary antibodies against CD31 (CST, 3528S, 1:200) and CD13 (Proteintech, 66211-1-Ig, 1:200).

    Techniques: Western Blot, Marker, Expressing, Extraction, Membrane, Enzyme-linked Immunosorbent Assay, Comparison